-+ 0.00%
-+ 0.00%
-+ 0.00%

Tempest Therapeutics Exercises Option To License Senlang’s CD7-Targeted Lentiviral Outside China

Benzinga·11/11/2026 13:54:49
Listen to the news

empest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates

-Lead BCMA/GPRC5D dual-targeting in vivo CAR-T candidate evaluated in 13 patients with relapsed or refractory multiple myeloma, including patients with extramedullary disease and prior CAR-T exposure

-Encouraging preliminary clinical responses support option exercise, results planned for presentation at a major scientific conference